Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 17/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.51 |
| ▸ | UGT1A4 | P22310 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17159812 | 0.86 | CYP19A1 (0.80) | CYP19A1HDAC1HDAC6UGT1A4PDE4D | |
| SCHEMBL15688800 | 0.80 | CYP19A1 (0.71) | CYP19A1HDAC1HDAC6 | |
| SCHEMBL2917482 | 0.80 | CYP19A1 (1.00) | CYP19A1HDAC1HDAC6 | |
| SCHEMBL2902764 | 0.79 | CYP19A1 (0.64) | CYP19A1HDAC1HDAC6UGT1A4PDE4D | |
| SCHEMBL11354103 | 0.78 | CYP19A1 (0.69) | CYP19A1HDAC1HDAC6 | |
| Hydrochloric Acid SCHEMBL9382670 | 0.78 | CYP19A1 (0.96) | CYP19A1HDAC1HDAC6 | |
| SCHEMBL3235365 | 0.78 | CYP19A1 (0.69) | CYP19A1HDAC1HDAC6 | |
| SCHEMBL309621 | 0.77 | CYP19A1 (0.67) | CYP19A1HDAC1HDAC6UGT1A4PDE4D | |
| Hydrochloric Acid SCHEMBL11358575 | 0.77 | CYP19A1 (0.67) | CYP19A1HDAC1HDAC6 | |
| SCHEMBL306232 | 0.77 | CYP19A1 (0.67) | CYP19A1HDAC1HDAC6UGT1A4PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008086158-A1 | BENZODIHYDROQUINAZOLINE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-17 | — | — | WO | claimed |
| CN-1393131-A | Antifungal triazole compounds | MILITARY MEDICAL UNIV NO 2 P L (CN) | 2003-01-29 | — | — | CN | claimed |
| EP-1194417-A1 | PHENOXY FLUOROPYRIMIDINES | BAYER AG (DE) | 2002-04-10 | — | — | EP | claimed |
| WO-2000078733-A1 | PHENOXY FLUOROPYRIMIDINES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-12-28 | — | — | WO | claimed |
| US-5866583-A | Substituted 2,4-diaminopyrimidines | HOFFMANN-LA ROCHE INC. (US) | 1999-02-02 | — | — | US | claimed |
| CN-113454086-A | Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR7 agonists | 百济神州有限公司 | 2021-09-28 | — | — | CN | disclosed |
| US-20120329784-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC | 2012-12-27 | — | — | US | disclosed |
| EP-2523559-A1 | COMPOUNDS AND METHODS | GlaxoSmithKline LLC (US) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011088031-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088027-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC (US) | 2011-07-21 | — | — | WO | disclosed |
| CN-102123991-A | 2-arylaminoquinazolines for the treatment of proliferative diseases | NOVARTIS AG | 2011-07-13 | — | — | CN | disclosed |
| WO-2008079988-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2011-05-12 | — | — | WO | disclosed |
| US-20050054851-A1 | Pyrrolo pyrimidines as agents for the inhibition of cystein proteases | NOVARTIS AG (CH) | 2005-03-10 | — | — | US | disclosed |
| EP-1423391-A1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | Novartis AG (CH) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003020721-A1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | NOVARTIS AG (CH) | 2003-03-13 | — | — | WO | disclosed |
| CN-1393131-A | Antifungal triazole compounds | MILITARY MEDICAL UNIV NO 2 P L (CN) | 2003-01-29 | — | — | CN | disclosed |
| EP-1194417-A1 | PHENOXY FLUOROPYRIMIDINES | BAYER AG (DE) | 2002-04-10 | — | — | EP | disclosed |
| WO-2000078733-A1 | PHENOXY FLUOROPYRIMIDINES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-12-28 | — | — | WO | disclosed |
| WO-1996002532-A1 | 7-SUBSTITUTED 1-[4-(1H-1,2,4-TRIAZOL-1-YL-METHYL)PHENYL] SUBSTITUTED QUINOLONE CARBOXYLIC ACIDS AS ANTIVIRAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1996-02-01 | — | — | WO | disclosed |
| WO-1996002532-A1 | 7-SUBSTITUTED 1-[4-(1H-1,2,4-TRIAZOL-1-YL-METHYL)PHENYL] SUBSTITUTED QUINOLONE CARBOXYLIC ACIDS AS ANTIVIRAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1996-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054851-A1 | Pyrrolo pyrimidines as agents for the inhibition of cystein proteases | CTSK, CTSS, CTSZ | CYP19A1 1054/4885HDAC1 2004/4885HDAC6 1018/4885 |
| US-20120329784-A1 | COMPOUNDS AND METHODS | RB1, DHFR, NQO1 | CYP19A1 30/4885HDAC1 410/4885HDAC6 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.